34,668 Shares in Lantheus Holdings, Inc. $LNTH Purchased by Polar Asset Management Partners Inc.

Key Points

• Polar Asset Management Partners Inc. has acquired a new stake in Lantheus Holdings, purchasing 34,668 shares valued at approximately $3.4 million, representing 0.05% of the company's stock.
• Several institutional investors, including Schonfeld Strategic Advisors LLC and Baird Financial Group Inc., have significantly increased their holdings in Lantheus, demonstrating growing confidence in the company's prospects.
• Despite recent insider sales totaling over $382 million, Lantheus reported earnings of $1.57 per share, missing analysts' estimates, with a projected average price target of $91.60 amidst a consensus rating of "Moderate Buy."

Polar Asset Management Partners Inc. bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 34,668 shares of the medical equipment provider's stock, valued at approximately $3,384,000. Polar Asset Management Partners Inc. owned about 0.05% of Lantheus at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Lantheus by 3.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock worth $1,162,000 after purchasing an additional 400 shares during the period. State of Alaska Department of Revenue increased its holdings in shares of Lantheus by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock valued at $794,000 after purchasing an additional 215 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Lantheus by 12,517.1% during the 1st quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock valued at $12,536,000 after buying an additional 127,424 shares during the period. Cetera Investment Advisers lifted its position in Lantheus by 21.4% in the first quarter. Cetera Investment Advisers now owns 28,362 shares of the medical equipment provider's stock valued at $2,768,000 after buying an additional 5,004 shares during the last quarter. Finally, Cerity Partners LLC boosted its position in shares of Lantheus by 12.7% during the first quarter. Cerity Partners LLC now owns 11,709 shares of the medical equipment provider's stock worth $1,143,000 after buying an additional 1,323 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Insider Activity at Lantheus

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This trade represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company's stock, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,812,000 shares of company stock worth $382,427,380. Corporate insiders own 2.00% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on LNTH shares. Truist Financial set a $63.00 price objective on Lantheus and gave the stock a "hold" rating in a report on Monday, August 11th. Mizuho reduced their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. B. Riley cut their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. JMP Securities reduced their price objective on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. Finally, William Blair reissued a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Four equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $91.60.

Lantheus Stock Performance

NASDAQ LNTH traded up $1.44 during trading hours on Tuesday, reaching $55.07. The company's stock had a trading volume of 1,033,721 shares, compared to its average volume of 1,645,782. The stock has a market cap of $3.74 billion, a PE ratio of 9.86 and a beta of 0.15. The business has a 50-day simple moving average of $65.54 and a 200 day simple moving average of $81.91. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $378.05 million during the quarter, compared to analyst estimates of $389.69 million. During the same period in the previous year, the company posted $1.80 earnings per share. Lantheus's revenue was down 4.1% compared to the same quarter last year. Equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.